Abstract:Introduction: Azole resistance has been increasingly reported and become an issue for clinical managements of invasive mycoses. New strategy with combination therapy arises as a valuable and promising alternative option. The aim of the present study is to investigate the in vitro combinational effect of proton pump inhibitors (PPIs) and azoles against pathogenic fungi. Methods: In vitro interactions of PPIs including omeprazole (OME), lansoprazole (LAN), pantoprazole (PAN), and rabeprazole (RAB), and commonly used azoles including itraconazole (ITC), posaconazole (POS), voriconazole (VRC) and FLC, were investigated via broth microdilution chequerboard procedure adapted from the CLSI M27-A3 and M38-A2. A total of 67 clinically isolated strains, namely 27 strains of Aspergillus spp., 16 strains of Candida spp., and 24 strains of dematiaceous fungi, were studied. C. parapsilosis (ATCC 22019) and A. flavus (ATCC 204304) was included to ensure quality control. Results: PPIs individually did not exert any significant antifungal activity. The combination of OME with ITC, POS, or VRC showed synergism against 77.6%, 86.6%, and 4% strains of tested pathogenic fungi, respectively, while synergism of OME/FLC was observed in 50% strains of Candida spp. Synergism between PAN and ITC, POS, or VRC was observed against 47.8%, 77.6% and 1.5% strains of tested fungi, respectively, while synergism of PNA/FLC was observed in 50% strains of Candida spp. Synergism of LAN with ITC, POS, or VRC was observed against 86.6%, 86.6%, and 3% of tested strains, respectively, while synergism of LAN/FLC was observed in 31.3% strains of Candida spp. Synergy of the combination of RAB with ITC, POS, or VRC was observed against 25.4%, 64.2%, and 4.5% of tested strains, respectively., synergism of RAB/FLC was observed in 12.5% of Candida spp.. Among PPIs, synergism was least observed between RAB and triazoles, while among triazoles, synergism was least observed between VRC and PPIs. Among species, synergy was much more frequently observed in Aspergillus spp. and dematiaceous fungi as compared to Candida spp. Antagonism between PPIs with ITC or VRC was occasionally observed in Aspergillus spp. and dematiaceous fungi. It is notable that PPIs combined with azoles showed synergy against azole resistant A. fumigatus , and resulted in category change of susceptibility of ITC and POS against Candida spp. Discussion: The results suggested that PPIs combined with azoles has the potential to enhance the susceptibilities of azoles against multiple pathogenic fungi and could be a promising strategy to overcome azole resistance issues. However, further investigations are warranted to study the combinational efficacy in more isolates and more species, to investigate the underlying mechanism of interaction and to evaluate the potential for concomitant use of these agents in human.

Itraconazole-Amphotericin B Antagonism inAspergillus fumigatus: an E-Test-Based Strategy

In Vitro Interaction of Itraconazole with Amphotericin B, Caspofungin, and Terbinafine Against Clinical Isolates of Trichosporon asahii

In Vitro Interactions of Micafungin with Amphotericin B, Itraconazole or Fluconazole Against the Pathogenic Phase of Penicillium Marneffei.

In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales

Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis

In Vitro and in Vivo Efficacy of a Synergistic Combination of Itraconazole and Verapamil Against Aspergillus Fumigatus

Isavuconazole and Amphotericin B Synergic Antifungal Activity: In Vitro Evaluation on Pulmonary Aspergillosis Molds Isolates

Berberine And Itraconazole Are Not Synergistic In Vitro Against Aspergillus Fumigatus Isolated From Clinical Patients

An in Vitro and in Vivo Study on the Synergistic Effect and Mechanism of Itraconazole or Voriconazole Alone and in Combination with Tetrandrine Against Aspergillus Fumigatus.

Antifungal susceptibility testing of clinical isolates of itraconazole-resistant Aspergillus fumigatus to four antifungal drugs

Increased frequency of non-fumigatus Aspergillus species in amphotericin B–or triazole–pre-exposed cancer patients with positive cultures for aspergilli

The interaction of echinocandin caspofungin with amphotericin B or voriconazole against the Aspergillus biofilms in vitro

Interaction of Amiodarone with Azoles Against Aspergillus Planktonic Cells and Biofilms in vitro

In Vitro Combined Activity of Amphotericin B, Caspofungin and Voriconazole Against Clinical Isolates of Trichosporon Asahii

In Vitro Susceptibility Testing of Aspergillus Spp. Against Voriconazole, Itraconazole, Posaconazole, Amphotericin B and Caspofungin

In vitro interactions of proton pump inhibitors and azoles against pathogenic fungi

In Vitro Interaction of Terbinafine with Itraconazole and Amphotericin B Against Fungi Causing Chromoblastomycosis in China.

In Vitro Interactions Between Antifungals and Methotrexate Against Aspergillus spp.

In Vitro Interactions Between Tacrolimus and Azoles Against Candida Albicans Determined by Different Methods.

Susceptibility Testing of the Combination of Itraconazole and Terbinafine in Vitro

Synergistic Effects of Tetrandrine with Posaconazole Against Aspergillus Fumigatus.